The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
[Antihypertensive effect of fosinopril in mild hypertension].
The aim of this double-blind r and omized placebo-controlled study was to evaluate the antihypertensive and safety of fosinopril in mild essential hypertension . After a 2-week placebo period , patients received either placebo or fosinopril 20 mg , once daily . Thirty-four patients finished the study ( 18 patients in the placebo group and 16 patients in the fosinopril group ) .  Systolic blood pressure decreased from 160.1 + /- 22.1 mmHg to 156.0 + /- 24.2 in the placebo group ( NS ) and from 151.8 + /- 14.0 mmHg to 141.5 + /- 14.5 in the fosinopril group ( p < 0.005 ) ; diastolic blood pressure decreased from 100.1 + /- 2.4 mmHg to 94.3 + /- 7.4 mmHg in the placebo group ( p < 0.005 ) and from 100.8 + /- 4.8 mmHg to 88.1 + /- 9.0 mmHg in the fosinopril group ( p < 0.001 ) . Mean decrease in diastolic blood pressure was 5.7 mmHg in the placebo group and 12.6 mmHg in the fosinopril group ( p < 0.05 ) . A statistically significant difference was seen between the percentage of controlled patients in the two groups : 16.6 % in the placebo group vs 56.2 % in the fosinopril group ( p < 0.05 ) . No statistically significant difference in biochemical parameters was seen between the two groups . Tolerance was good and no patients were withdrawn from the study for adverse events
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .